Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Central venous catheterisation? 70 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 70 reports of Central venous catheterisation have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.1% of all adverse event reports for PEMBROLIZUMAB.

70
Reports of Central venous catheterisation with PEMBROLIZUMAB
0.1%
of all PEMBROLIZUMAB reports
13
Deaths
30
Hospitalizations

How Dangerous Is Central venous catheterisation From PEMBROLIZUMAB?

Of the 70 reports, 13 (18.6%) resulted in death, 30 (42.9%) required hospitalization, and 3 (4.3%) were considered life-threatening.

Is Central venous catheterisation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 70 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Central venous catheterisation?

EPOPROSTENOL (361) AMBRISENTAN (263) TREPROSTINIL (208) ECULIZUMAB (105) VENETOCLAX (89) MACITENTAN (78) AZTREONAM LYSINE (63) ADALIMUMAB (59) NATALIZUMAB (57) GLYCINE\MANNITOL\SODIUM (56)

Which PEMBROLIZUMAB Alternatives Have Lower Central venous catheterisation Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Central venous catheterisation Reports All Drugs Causing Central venous catheterisation PEMBROLIZUMAB Demographics